All Categories
Categories
Contributors
Dr Emma Woodward is a Consultant clinical Geneticist and Honorary Senior Clinical Lecturer. High-risk single gene disorders account for ≈5-10% of cancers with lower risk alleles accounting for a further ≈10-15%. This patient group are unique in having a markedly elevated lifetime risk of developing particular cancer types and propensity to multiple primary tumours. However, there are significant opportunities for cancer prevention and early detection strategies in the individual and their at-risk family members. Here I discuss how cancer prevention and early detection care of these patients and their families reduces cancer burden and provides unique insights into underlying biology and opportunities for novel research strategies.
67
7/8/2021
Dr Christian von Wagner is a Reader at the Department of Behavioural Science and Health, at the Institute of Epidemiology & Health Care. His presentation will illustrate the role of behavioural science in improving cancer outcomes through the study of cancer screening, measuring patient experiences/preferences and assessing knowledge, attitudes and beliefs about cancer. He will give examples of how behavioural science can use an experimental medicine approach to identify new targets and strategies to reduce socioeconomic inequalities in cancer screening; how to reduce structural barriers to help seeking and cancer screening by understanding the role of allied health professionals and develop and evaluate community-based interventions.
61
3/2/2021
Nora Pashayan is a Professor of Applied Cancer Research at UCL Institute of Epidemiology and Healthcare and an Honorary Consultant in Public Health Medicine. She is qualified in medicine (American University of Beirut), specialized in both family medicine and public health medicine, and qualified in both epidemiology (LSHTM) and public health (University of Cambridge). Nora’s research is in risk-stratified cancer screening, from modeling the natural history of cancer, identifying risk-stratified screening strategies that optimise the benefit-harm balance and the cost-effectiveness of the screening programmes, to preparing for implementation of such programmes.
In this session, Nora will cover how early is early, why one-size does not fit all, and how risk-stratification could optimise the benefit-harm balance of early detection programmes.
109
7/24/2020